{
    "name": "revefenacin",
    "comment": "Rx",
    "other_names": [
        "Yupelri"
    ],
    "classes": [
        "Anticholinergics",
        "Inhaled"
    ],
    "source": "https://reference.medscape.com/drug/yupelri-revefenacin-1000265",
    "pregnancy": {
        "common": [
            "There are no available data regarding use in pregnant women",
            "Advise women to contact their physician if they become pregnant while taking revefenacin"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Data are not available regarding presence of revefenacin in human milk, effects on breastfed infant, or effects on milk production",
            "Present in milk of lactating rats following dosing during pregnancy and lactation",
            "Consider the development and health benefits of breastfeeding along with the mother’s clinical need for the drug and any potential adverse effects on the breastfed child or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Do not initiate during acutely deteriorating or life-threatening COPD episodes; intended as maintenance treatment and not for relief of acute symptoms",
                "Inhalers can produce paradoxical bronchospasm that may be life-threatening; if this occurs, treat immediately with an inhaled, short-acting bronchodilator and discontinue revefenacin",
                "Caution with narrow-angle glaucoma; instruct patients to contact physician if symptoms occur (eg, eye pain, blurred vision, visual halos, colored images, red eyes from congestion, corneal edema)",
                "May worsen urinary retention, especially with history of prostatic hyperplasia or bladder-neck obstruction",
                "Immediate hypersensitivity reported; discontinue drug immediately"
            ],
            "specific": [
                {
                    "type": "Reevaluate COPD treatment immediately if ",
                    "description": [
                        "Therapy no longer controls bronchoconstriction symptoms",
                        "Inhaled short-acting beta2-agonist becomes less effective",
                        "More inhalations of a short-acting beta2-agonist are needed or exceed recommended maximum dose"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Avoid coadministration with other anticholinergic drugs, owing to additive effects",
                        "OATP1B1 and OATP1B3 inhibitors may increase systemic exposure of revefenacin’s active metabolite; coadministration not recommended"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "aclidinium",
            "description": {
                "common": "revefenacin and aclidinium both decrease  cholinergic effects/transmission. Avoid or Use Alternate Drug. Coadministration may cause additive anticholinergic effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atropine",
            "description": {
                "common": "revefenacin and atropine both decrease  cholinergic effects/transmission. Avoid or Use Alternate Drug. Coadministration may cause additive anticholinergic effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "benztropine",
            "description": {
                "common": "revefenacin and benztropine both decrease  cholinergic effects/transmission. Avoid or Use Alternate Drug. Coadministration may cause additive anticholinergic effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "cyclosporine increases levels of revefenacin by Other (see comment). Avoid or Use Alternate Drug. \nComment: OATP1B1 and OATP1B3 transport inhibitors may increase systemic exposure of revefenacin's active metabolite. Coadministration not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "darifenacin",
            "description": {
                "common": "revefenacin and darifenacin both decrease  cholinergic effects/transmission. Avoid or Use Alternate Drug. Coadministration may cause additive anticholinergic effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dicyclomine",
            "description": {
                "common": "revefenacin and dicyclomine both decrease  cholinergic effects/transmission. Avoid or Use Alternate Drug. Coadministration may cause additive anticholinergic effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erythromycin base",
            "description": {
                "common": "erythromycin base increases levels of revefenacin by Other (see comment). Avoid or Use Alternate Drug. \nComment: OATP1B1 and OATP1B3 transport inhibitors may increase systemic exposure of revefenacin's active metabolite. Coadministration not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erythromycin ethylsuccinate",
            "description": {
                "common": "erythromycin ethylsuccinate increases levels of revefenacin by Other (see comment). Avoid or Use Alternate Drug. \nComment: OATP1B1 and OATP1B3 transport inhibitors may increase systemic exposure of revefenacin's active metabolite. Coadministration not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erythromycin lactobionate",
            "description": {
                "common": "erythromycin lactobionate increases levels of revefenacin by Other (see comment). Avoid or Use Alternate Drug. \nComment: OATP1B1 and OATP1B3 transport inhibitors may increase systemic exposure of revefenacin's active metabolite. Coadministration not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erythromycin stearate",
            "description": {
                "common": "erythromycin stearate increases levels of revefenacin by Other (see comment). Avoid or Use Alternate Drug. \nComment: OATP1B1 and OATP1B3 transport inhibitors may increase systemic exposure of revefenacin's active metabolite. Coadministration not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fesoterodine",
            "description": {
                "common": "revefenacin and fesoterodine both decrease  cholinergic effects/transmission. Avoid or Use Alternate Drug. Coadministration may cause additive anticholinergic effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "gemfibrozil",
            "description": {
                "common": "gemfibrozil increases levels of revefenacin by Other (see comment). Avoid or Use Alternate Drug. \nComment: OATP1B1 and OATP1B3 transport inhibitors may increase systemic exposure of revefenacin's active metabolite. Coadministration not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "glecaprevir/pibrentasvir",
            "description": {
                "common": "glecaprevir/pibrentasvir increases levels of revefenacin by Other (see comment). Avoid or Use Alternate Drug. \nComment: OATP1B1 and OATP1B3 transport inhibitors may increase systemic exposure of revefenacin's active metabolite. Coadministration not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "glycopyrrolate",
            "description": {
                "common": "revefenacin and glycopyrrolate both decrease  cholinergic effects/transmission. Avoid or Use Alternate Drug. Coadministration may cause additive anticholinergic effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "glycopyrrolate inhaled",
            "description": {
                "common": "revefenacin and glycopyrrolate inhaled both decrease  cholinergic effects/transmission. Avoid or Use Alternate Drug. Coadministration may cause additive anticholinergic effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hyoscyamine",
            "description": {
                "common": "revefenacin and hyoscyamine both decrease  cholinergic effects/transmission. Avoid or Use Alternate Drug. Coadministration may cause additive anticholinergic effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hyoscyamine spray",
            "description": {
                "common": "revefenacin and hyoscyamine spray both decrease  cholinergic effects/transmission. Avoid or Use Alternate Drug. Coadministration may cause additive anticholinergic effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ipratropium",
            "description": {
                "common": "revefenacin and ipratropium both decrease  cholinergic effects/transmission. Avoid or Use Alternate Drug. Coadministration may cause additive anticholinergic effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "leniolisib",
            "description": {
                "common": "leniolisib will increase the level or effect of revefenacin by  Other (see comment). Avoid or Use Alternate Drug. Leniolisib, an OATP1B1 and OATP1B3 inhibitor, may increase systemic exposure of these substrates "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methscopolamine",
            "description": {
                "common": "revefenacin and methscopolamine both decrease  cholinergic effects/transmission. Avoid or Use Alternate Drug. Coadministration may cause additive anticholinergic effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC)",
            "description": {
                "common": "ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) increases levels of revefenacin by Other (see comment). Avoid or Use Alternate Drug. \nComment: OATP1B1 and OATP1B3 transport inhibitors may increase systemic exposure of revefenacin's active metabolite. Coadministration not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pazopanib",
            "description": {
                "common": "pazopanib increases levels of revefenacin by Other (see comment). Avoid or Use Alternate Drug. \nComment: OATP1B1 and OATP1B3 transport inhibitors may increase systemic exposure of revefenacin's active metabolite. Coadministration not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "propantheline",
            "description": {
                "common": "revefenacin and propantheline both decrease  cholinergic effects/transmission. Avoid or Use Alternate Drug. Coadministration may cause additive anticholinergic effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin increases levels of revefenacin by Other (see comment). Avoid or Use Alternate Drug. \nComment: OATP1B1 and OATP1B3 transport inhibitors may increase systemic exposure of revefenacin's active metabolite. Coadministration not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifamycin",
            "description": {
                "common": "rifamycin increases levels of revefenacin by Other (see comment). Avoid or Use Alternate Drug. \nComment: OATP1B1 and OATP1B3 transport inhibitors may increase systemic exposure of revefenacin's active metabolite. Coadministration not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir increases levels of revefenacin by Other (see comment). Avoid or Use Alternate Drug. \nComment: OATP1B1 and OATP1B3 transport inhibitors may increase systemic exposure of revefenacin's active metabolite. Coadministration not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "solifenacin",
            "description": {
                "common": "revefenacin and solifenacin both decrease  cholinergic effects/transmission. Avoid or Use Alternate Drug. Coadministration may cause additive anticholinergic effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "tacrolimus increases levels of revefenacin by Other (see comment). Avoid or Use Alternate Drug. \nComment: OATP1B1 and OATP1B3 transport inhibitors may increase systemic exposure of revefenacin's active metabolite. Coadministration not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "telmisartan",
            "description": {
                "common": "telmisartan increases levels of revefenacin by Other (see comment). Avoid or Use Alternate Drug. \nComment: OATP1B1 and OATP1B3 transport inhibitors may increase systemic exposure of revefenacin's active metabolite. Coadministration not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tiotropium",
            "description": {
                "common": "revefenacin and tiotropium both decrease  cholinergic effects/transmission. Avoid or Use Alternate Drug. Coadministration may cause additive anticholinergic effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tolterodine",
            "description": {
                "common": "revefenacin and tolterodine both decrease  cholinergic effects/transmission. Avoid or Use Alternate Drug. Coadministration may cause additive anticholinergic effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trihexyphenidyl",
            "description": {
                "common": "revefenacin and trihexyphenidyl both decrease  cholinergic effects/transmission. Avoid or Use Alternate Drug. Coadministration may cause additive anticholinergic effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trofinetide",
            "description": {
                "common": "trofinetide will increase the level or effect of revefenacin by  Other (see comment). Avoid or Use Alternate Drug. rofinetide (an OATP131 and OATP13B inhibitor) may increase plasma levels of OATP131 or OATP13B substrates. Avoid coadministration with sensitive substrates."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trospium chloride",
            "description": {
                "common": "revefenacin and trospium chloride both decrease  cholinergic effects/transmission. Avoid or Use Alternate Drug. Coadministration may cause additive anticholinergic effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "umeclidinium bromide",
            "description": {
                "common": "revefenacin and umeclidinium bromide both decrease  cholinergic effects/transmission. Avoid or Use Alternate Drug. Coadministration may cause additive anticholinergic effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "umeclidinium bromide/vilanterol inhaled",
            "description": {
                "common": "revefenacin and umeclidinium bromide/vilanterol inhaled both decrease  cholinergic effects/transmission. Avoid or Use Alternate Drug. Coadministration may cause additive anticholinergic effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "velpatasvir",
            "description": {
                "common": "velpatasvir increases levels of revefenacin by Other (see comment). Avoid or Use Alternate Drug. \nComment: OATP1B1 and OATP1B3 transport inhibitors may increase systemic exposure of revefenacin's active metabolite. Coadministration not recommended."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "donepezil transdermal",
            "description": {
                "common": "donepezil transdermal, revefenacin.\nEither decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "encorafenib",
            "description": {
                "common": "encorafenib will increase the level or effect of revefenacin by  Other (see comment). Modify Therapy/Monitor Closely. Encorafenib (a OATP1B1 and OATP1B3 inhibitor) may increase the concentration and toxicities of OATP1B1 and OATP1B3 substrates. Closely monitor for signs and symptoms of increased exposure and consider adjusting the dose of these substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fostemsavir",
            "description": {
                "common": "fostemsavir will increase the level or effect of revefenacin by  Other (see comment). Modify Therapy/Monitor Closely. Fostemsavir inhibits OATP1B1/3 transporter. If possible, avoid coadministration or modify dose of OATP1B1/3 substrates coadministered with fostemsavir. "
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Cough",
            "percent": "4"
        },
        {
            "name": "Nasopharyngitis",
            "percent": "4"
        },
        {
            "name": "Headache",
            "percent": "4"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "3"
        },
        {
            "name": "Back pain",
            "percent": "2"
        },
        {
            "name": "Hypertension",
            "percent": "1-2"
        },
        {
            "name": "Dizziness",
            "percent": "1-2"
        },
        {
            "name": "Oropharyngeal pain",
            "percent": "1-2"
        },
        {
            "name": "Bronchitis",
            "percent": "1-2"
        },
        {
            "name": "Paradoxical bronchospasm",
            "percent": null
        },
        {
            "name": "Worsening narrow",
            "percent": null
        },
        {
            "name": "angle glaucoma",
            "percent": null
        },
        {
            "name": "Worsening urinary retention",
            "percent": null
        },
        {
            "name": "Immediate hypersensitivity reactions",
            "percent": null
        },
        {
            "name": "Dry mouth",
            "percent": null
        }
    ]
}